Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Completed · Not applicable

Conditions studied: Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia

In brief

The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing between 500 and 1250 grams at birth. Babies are enrolled between Day of Life 3 and 5. Babies are randomized to either Veronate or placebo (50-50 chance of either). Babies can receive up to 4 doses of the study drug on Study Days 1, 3, 8 and 15 and are followed until Study Day 70 or discharge from the hospital.

Key facts

Study ID

NCT00113191

Run by

Bristol-Myers Squibb

People needed

2000

Starts

2004-05-01

Expected to finish

2006-06-01

Last updated by the study team

2012-08-02

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained from parent or legal guardian
• Birth weight 500 to 1250 g, inclusive
• Age 3 - 5 days (49 to 120 hours), inclusive
• Expected to require IV access for medical care through day of life 14

You may not qualify if…

• Already received or likely to receive prior to first infusion of Study Drug:
• IGIV or *immune globulin for prevention of Hepatitis B
• Receiving an agent for prevention of staphylococcal catheter related or nosocomial infections (e.g., vancomycin)
• Active sepsis, as defined by one of the following:
• culture proven early onset sepsis and not clinically stable; or
• clinical signs of sepsis and pending blood cultures; if the blood cultures are negative after 48 hours and the infant is clinically stable, the infant may be randomized
• Severe congenital anomaly, where the prospects for survival, the medical complications and treatment, would compromise the study related outcome evaluation(s) in the Investigator's opinion
• Diagnosis of congenital immunodeficiency
• Evidence of significant fluid overload or significant volume depletion
• Evidence of abnormal renal function as measured by serum creatinine > 1.6 mg/dL

Where it is running

• Study site — Mobile, Alabama, United States
• Study site — Anchorage, Alaska, United States
• Study site — Phoenix, Arizona, United States
• Study site — Phoenix, Arizona, United States
• Study site — Phoenix, Arizona, United States
• Study site — Hayward, California, United States
• Study site — Loma Linda, California, United States
• Study site — Long Beach, California, United States
• Study site — Oakland, California, United States
• Study site — Oakland, California, United States
• Study site — Orange, California, United States
• Study site — Sacramento, California, United States
• Study site — San Francisco, California, United States
• Study site — San Francisco, California, United States
• Study site — Santa Clara, California, United States
• Study site — Walnut Creek, California, United States
• Study site — Newark, Delaware, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Gainesville, Florida, United States
• Study site — Hollywood, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.